Stock analysts at StockNews.com began coverage on shares of Oragenics (NYSE:OGEN – Get Rating) in a research report issued on Thursday. The firm set a "sell" rating on the stock.

Oragenics Price Performance

NYSE OGEN opened at $3.43 on Thursday. The business has a fifty day moving average price of $4.71 and a two-hundred day moving average price of $1.90. The stock has a market capitalization of $6.72 million, a PE ratio of -0.44 and a beta of 0.37. Oragenics has a fifty-two week low of $2.61 and a fifty-two week high of $24.00.

About Oragenics

(Get Rating)

Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Further Reading

• Get a free copy of the StockNews.com research report on Oragenics (OGEN)
• Penny Stock Wag! Group Co. Has Solid Sell-Side Support
• Staples Stocks Get Lift From Conagra Results, New Highs In Sight
• SGH Bottomed, But Can It Reverse And Move Higher?
• Is Pinterest Showing Signs of an Improving Ad Market?
• At 3x Earnings, Avis Budget Is Worth Taking for a Spin

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.